Could a simple shot replace IV drips for lung cancer immunotherapy?

NCT ID NCT06091943

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether an immunotherapy drug called tislelizumab can be given as a simple injection under the skin instead of through an IV drip for people with advanced non-small cell lung cancer. The study will compare how well the body absorbs the drug in both forms, when used alongside standard chemotherapy as the first treatment. The goal is to see if the easier injection method works just as well, which could make treatment more convenient for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (an immunotherapy drug) given as a subcutaneous injection or intravenously, combined with chemotherapy
What this could lead to: If successful, this could offer a more convenient way to deliver immunotherapy for lung cancer, potentially improving patient comfort and access.
What could go wrong: This is an early-phase study, so the subcutaneous form may not match the IV version in effectiveness or safety. Results are preliminary and need confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Arensia Exploratory Medicine Llc

Tbilisi, 0112, Georgia
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Deyangs People Hospital

Deyang, Sichuan, 618000, China
Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
Huzhou Central Hospital

Huzhou, Zhejiang, 313003, China
Jining No Peoples Hospital East Branch

Jining, Shandong, 272002, China
Mengchao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, Fujian, 350025, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Shanxi Bethune Hospital

Taiyuan, Shanxi, 030032, China
Shanxi Provincial Cancer Hospital

Taiyuan, Shanxi, 030013, China
The First Affiliated Hospital of Nanchang University Branch Donghu

Nanchang, Jiangxi, 330006, China
The Institute of Oncology, Arensia Exploratory Medicine

Chisinau, 2025, Moldova

More trials for these conditions

Other studies related to the condition(s) this trial covers.